Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Useful Contacts |
  6. Site Map |
  7. Help
  1. Font size

    Reduce font size Increase font size  
 
 
News

Sub-section menu :

Content :

Valproate Educational Materials – Risk in Pregnancy

Sanofi is dedicated to the ongoing safety surveillance and proactive risk management of all our products.

In line with our global team response, Sanofi wants to ensure patients understand the risks associated with valproate in female children, women of childbearing potential and pregnant women educational materials are being made available to healthcare professionals and patients.

The educational materials consist of:

Call for reporting

Please remember that any suspected adverse events should be reported to the Therapeutic Goods Administration (TGA), using the following link https://www.tga.gov.au/reporting-problems#medicine or to Medsafe using the following link http://www.medsafe.govt.nz/safety/report-a-problem.asp

Company Contact

Adverse reactions can also be reported directly to Sanofi: email ae@sanofi.com or at telephone number 02 8666 2123. Our medical information department can be contacted for further information at medinfo.australia@sanofi.com or at telephone number 1800 818 806 or 0800 283 648.

Updated: June 01, 2015

Module :

Corporate information

Corporate information